Sign up to save your podcasts
Or
Share ASCO 2026 Plenary: RASolute-302
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
ASCO 2026 Plenary: RASolute-302
This week’s episode will be focusing on the 2026 ASCO Plenary that received a standing ovation, the RASolute 302 trial.
The RASolute 302 trial is a landmark phase 3 study demonstrating that daraxonrasib doubled overall survival compared to chemotherapy in previously treated (2L) metastatic pancreatic ductal adenocarcinoma (mPDAC).
View all episodes
By Sam and Karine
4.8
193193 ratings
This week’s episode will be focusing on the 2026 ASCO Plenary that received a standing ovation, the RASolute 302 trial.
The RASolute 302 trial is a landmark phase 3 study demonstrating that daraxonrasib doubled overall survival compared to chemotherapy in previously treated (2L) metastatic pancreatic ductal adenocarcinoma (mPDAC).
More shows like Two Onc Docs
View all
NEJM This Week
319 Listeners
JAMA Clinical Reviews
506 Listeners
Journal of Clinical Oncology (JCO) Podcast
40 Listeners
Research To Practice | Oncology Videos
122 Listeners
ASCO Daily News
57 Listeners
The Curbsiders Internal Medicine Podcast
3,360 Listeners
Core IM | Internal Medicine Podcast
1,152 Listeners
OncoPharm
188 Listeners
ASCO Guidelines
47 Listeners
The Clinical Problem Solvers
517 Listeners
Harrison's PodClass: Internal Medicine Cases and Board Prep
373 Listeners
Blood Podcast
51 Listeners
Oncology Today with Dr Neil Love
59 Listeners
Blood Cancer Talks
51 Listeners
Oncology Brothers: Practice-Changing Cancer Discussions
46 Listeners